Mesoblast (NASDAQ:MESO) Shares Gap Down – Here’s What Happened

Mesoblast Limited (NASDAQ:MESO)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $14.87, but opened at $13.88. Mesoblast shares last traded at $13.7960, with a volume of 101,995 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mesoblast in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold”.

Mesoblast Trading Up 1.7%

The company has a quick ratio of 1.41, a current ratio of 1.58 and a debt-to-equity ratio of 0.10. The business has a fifty day simple moving average of $15.76 and a 200 day simple moving average of $16.84. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -25.78 and a beta of 2.19.

Mesoblast (NASDAQ:MESO) last released its earnings results on Thursday, January 29th. The company reported ($0.16) EPS for the quarter. The business had revenue of $25.67 million during the quarter. On average, equities analysts anticipate that Mesoblast Limited will post -0.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Mesoblast

A number of hedge funds and other institutional investors have recently bought and sold shares of MESO. Legal & General Group Plc acquired a new stake in Mesoblast in the third quarter valued at $10,501,000. Goldman Sachs Group Inc. acquired a new stake in Mesoblast in the first quarter valued at $3,209,000. Bank of America Corp DE lifted its holdings in Mesoblast by 791.7% in the third quarter. Bank of America Corp DE now owns 111,459 shares of the company’s stock valued at $1,796,000 after acquiring an additional 98,960 shares during the period. Rialto Wealth Management LLC acquired a new stake in Mesoblast in the fourth quarter valued at $839,000. Finally, Brooklyn Investment Group purchased a new position in shares of Mesoblast in the third quarter valued at $655,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.